MCM
ARMP icon

MAI Capital Management’s Armata Pharmaceuticals ARMP Stock Holding History

MAI Capital Management’s Portfolio ARMP Stock Details ARMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-71
Closed -$728 – 2255
2026
Q1 		$728 Hold
71
– – ﹤0.01% 4292
2025
Q4 		$446 Hold
71
– – ﹤0.01% 3862
2025
Q3 		$212 Hold
71
– – ﹤0.01% 3705
2025
Q2 		$135 Hold
71
– – ﹤0.01% 3883
2025
Q1 		$104 Hold
71
– – ﹤0.01% 3350
2024
Q4 		$132 Buy
+71
New +$160 ﹤0.01% 3410

Other funds holding ARMP

MAM
Madison Asset Management Madison, Wisconsin $8.39B AUM 16.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

MAI Capital Management's ARMP Position: Q2 2026 in Review

MAI Capital Management sold out of Armata Pharmaceuticals (ARMP) in Q2 2026, closing a stake of 71 shares — an estimated $728 sold.

MAI Capital Management first reported a position in ARMP in Q4 2024 and held it in 6 quarters. The position peaked at $728 in Q1 2026. 53 funds tracked by Wall St. Rank hold ARMP as of Q2 2026.

  • MAI Capital Management reported no remaining Armata Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 71 Armata Pharmaceuticals shares in Q2 2026, an estimated $728.
  • MAI Capital Management first reported a position in Armata Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Armata Pharmaceuticals position peaked at $728 in Q1 2026.
  • 53 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.